After hosting investor meetings with management, Jefferies analyst Michael Yee concluded that despite the "visceral market reaction," investors who "understand the details" come away with a consensus view that bempedoic acid is not causing cancer and not causing cardiovascular deaths. This is positive and a "stock repair" could happen if the company lays out the details of the deaths clearly and the three studies coming in May, August and September support a positive safety picture, Yee tells investors in a research note. He has a Buy rating on Esperion with an $85 price target.